Amgen taps Syapse to infuse real-world data into its cancer clinical trial designs

Amgen Oncology_Insight
Amgen, through its venture fund, previously participated in Syapse’s $30 million series D round alongside the corporate financing arms of Merck and Roche. (Amgen Oncology)

Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development.

Together, Amgen and Syapse will develop observational research analytics aimed at assessing outcomes in areas of unmet need—starting by identifying existing patients within Syapse’s health network that may be eligible for clinical trials, and then bringing those studies to nearby sites.

In addition, Amgen will be able to tap into Syapse’s collection of real-world data, which it may use to support future regulatory filings for a selection of cancer drug candidates. The two companies will also work to develop new evidence standards in the field.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients," Amgen’s senior vice president of strategy, commercialization and innovation, Mike Nohaile, said in a statement.

RELATED: Amgen, Merck, Roche get in on Syapse’s $30M round

Amgen, through its venture fund, previously participated in Syapse’s $30 million series D round in November 2017—alongside Medidata Solutions and the corporate financing arms of Merck and Roche. The San Francisco-based company’s previous backers include Ascension Ventures, GE Ventures and Intermountain Healthcare Innovation Fund.

Syapse’s oncology software platform is designed to help healthcare providers offer precision medicine consistently, including through clinical trials, and supplies them with real-world information about treatments and outcomes through a data-sharing network.

"Through this collaboration and the strategic relationships we've built with community health systems globally, we aim to develop evidence of clinical utility that can be used to bring molecularly targeted treatments to market more quickly and ensure more diverse groups of patients can access them," said Syapse CEO Ken Tarkoff.

RELATED: Concerto HealthAI signs on with Pfizer to apply real-world data to precision cancer medicine

Elsewhere, Concerto HealthAI has inked two Big Pharma collaborations in the past two months, focused on using real-world data to help design more efficient oncology clinical trials for Pfizer and Bristol-Myers Squibb, including synthetic control arm studies and measurements of economic outcomes.

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.